Single doses of all-trans-N-retinylacetamide slow down the ERG amplitude recovery after bleaching in rats
- PMID: 20012154
- DOI: 10.1007/s10633-009-9209-2
Single doses of all-trans-N-retinylacetamide slow down the ERG amplitude recovery after bleaching in rats
Abstract
To assess the safety and to quantify the effects of a single application of all-trans-N-retinylacetamide on the rat retina measured by electroretinography (ERG). Brown Norway rats were assigned to either a control group (n = 13) or to one of the three groups treated with a single intra-peritoneal dose of all-trans-N-retinylacetamide: 20 (n = 8), 5 (n = 7), or 1 mg/kg (n = 8). Full-field ERGs were performed 7 days before (baseline) and 12 h after treatment. Intensity-response relationship of b-wave amplitudes were evaluated in dark-adapted conditions using white stimuli (0.000003-0.3 cd.s/m(2)). Fast dynamics of rod sensitivity was assessed by a paired-flash paradigm; recovery dynamics of b-wave amplitudes after bleaching was followed for 70 min. Light-adapted ERGs were recorded for cone evaluation. No effects were found on either dark-adapted sensitivity or on fast rod recovery. However, drug treatment at 5 and 20 mg/kg significantly delayed ERG amplitude recovery after bleaching: 60 min after bleaching the b-wave amplitude was 21 + or - 9% (P < 0.05) and 66 + or - 10% (P < 0.05), respectively, compared to baseline. Recovery rates returned to normal 8 weeks after treatment. There were no changes in light-adapted ERG in any group. Systemic administration of a single dose of the visual cycle modulator all-trans-N-retinylacetamide reversibly delayed recovery of dark-adapted ERG amplitudes after bleaching, leaving other functions unchanged. This finding could make the compound potentially useful in experimental conditions or in specific diseases where the visual cycle is involved, such as retinitis pigmentosa or age-related macular degeneration.
Similar articles
-
Short-term inter-visit variability of erg amplitudes in normal subjects and patients with retinitis pigmentosa.Retina. 2005 Dec;25(8):1014-21. doi: 10.1097/00006982-200512000-00010. Retina. 2005. PMID: 16340532
-
Full-field electroretinogram in autism spectrum disorder.Doc Ophthalmol. 2016 Apr;132(2):83-99. doi: 10.1007/s10633-016-9529-y. Epub 2016 Feb 11. Doc Ophthalmol. 2016. PMID: 26868825
-
Toluene inhalation exposure for 13 weeks causes persistent changes in electroretinograms of Long-Evans rats.Neurotoxicology. 2016 Mar;53:257-270. doi: 10.1016/j.neuro.2016.02.008. Epub 2016 Feb 17. Neurotoxicology. 2016. PMID: 26899397 Free PMC article.
-
Correlations Between Dark-Adapted Rod Threshold Elevations and ERG Response Deficits in Duchenne Muscular Dystrophy.Invest Ophthalmol Vis Sci. 2021 Apr 1;62(4):29. doi: 10.1167/iovs.62.4.29. Invest Ophthalmol Vis Sci. 2021. PMID: 33891680 Free PMC article.
-
The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa.Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1693-8. Invest Ophthalmol Vis Sci. 1996. PMID: 8675413 Review.
Cited by
-
Advances and therapeutic opportunities in visual cycle modulation.Prog Retin Eye Res. 2025 May;106:101360. doi: 10.1016/j.preteyeres.2025.101360. Epub 2025 Apr 23. Prog Retin Eye Res. 2025. PMID: 40280538 Free PMC article. Review.
-
Assessment of "non-recordable" electroretinograms by 9 Hz flicker stimulation under scotopic conditions.Doc Ophthalmol. 2012 Feb;124(1):27-39. doi: 10.1007/s10633-011-9302-1. Epub 2011 Dec 18. Doc Ophthalmol. 2012. PMID: 22179598
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources